Protalix BioTherapeutics (PLX) Competitors $2.60 +0.17 (+7.00%) Closing price 04:00 PM EasternExtended Trading$2.58 -0.02 (-0.77%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. NRIX, DNA, TERN, ANAB, PVLA, MGTX, SIGA, OLMA, KROS, and BCAXShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Nurix Therapeutics (NRIX), Ginkgo Bioworks (DNA), Terns Pharmaceuticals (TERN), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), MeiraGTx (MGTX), Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Nurix Therapeutics Ginkgo Bioworks Terns Pharmaceuticals AnaptysBio Palvella Therapeutics MeiraGTx Siga Technologies Olema Pharmaceuticals Keros Therapeutics Bicara Therapeutics Protalix BioTherapeutics (NYSE:PLX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Does the media refer more to PLX or NRIX? In the previous week, Nurix Therapeutics had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Nurix Therapeutics and 0 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.38 beat Nurix Therapeutics' score of 0.74 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Overall Sentiment Protalix BioTherapeutics Positive Nurix Therapeutics Positive Is PLX or NRIX more profitable? Protalix BioTherapeutics has a net margin of -21.03% compared to Nurix Therapeutics' net margin of -234.57%. Protalix BioTherapeutics' return on equity of -30.89% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Nurix Therapeutics -234.57%-45.26%-34.71% Do analysts prefer PLX or NRIX? Protalix BioTherapeutics presently has a consensus price target of $15.00, indicating a potential upside of 476.92%. Nurix Therapeutics has a consensus price target of $29.07, indicating a potential upside of 192.18%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nurix Therapeutics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Which has more volatility & risk, PLX or NRIX? Protalix BioTherapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Do insiders & institutionals believe in PLX or NRIX? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, PLX or NRIX? Protalix BioTherapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$61.95M3.35$8.31M$0.0737.14Nurix Therapeutics$54.55M13.94-$193.57M-$2.61-3.81 SummaryProtalix BioTherapeutics beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$207.30M$355.39M$6.15B$22.11BDividend YieldN/AN/A5.64%3.56%P/E Ratio-20.00N/A85.6629.95Price / Sales3.35436.97527.3670.47Price / Cash17.8022.4426.3018.33Price / Book5.533.8812.924.65Net Income$8.31M-$133.30M$3.30B$1.01B7 Day Performance20.37%6.44%4.80%1.21%1 Month Performance68.83%17.89%8.11%3.21%1 Year Performance140.74%15.64%75.85%14.02% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.8571 of 5 stars$2.60+7.0%$15.00+476.9%+125.0%$207.30M$61.95M-20.00200NRIXNurix Therapeutics2.1178 of 5 stars$9.28+3.9%$29.07+213.3%-57.7%$682.69M$54.55M-3.56300Upcoming EarningsDNAGinkgo Bioworks1.5701 of 5 stars$13.20+14.8%$9.00-31.8%+93.7%$680.80M$227.04M-2.25640TERNTerns Pharmaceuticals3.8634 of 5 stars$7.79+2.0%$15.49+98.8%-0.5%$668.58MN/A-7.4940Gap UpANABAnaptysBio2.5634 of 5 stars$23.27-1.3%$46.13+98.2%-8.9%$660.17M$91.28M-5.19100Analyst RevisionPVLAPalvella Therapeutics2.2471 of 5 stars$62.25+4.5%$67.09+7.8%N/A$659.04M$42.81M-5.14N/AMGTXMeiraGTx3.9313 of 5 stars$8.25+0.9%$24.00+190.9%+103.6%$658.06M$33.28M-4.04300Positive NewsGap UpSIGASiga Technologies1.8885 of 5 stars$8.96-2.2%N/A+28.2%$655.91M$138.72M7.9340News CoveragePositive NewsOLMAOlema Pharmaceuticals2.8915 of 5 stars$9.54+0.3%$24.00+151.6%-4.3%$652.71MN/A-4.8270KROSKeros Therapeutics2.1225 of 5 stars$15.95-0.6%$30.00+88.1%-73.8%$651.88M$3.55M51.45100BCAXBicara Therapeutics2.3411 of 5 stars$13.87+18.4%$32.25+132.5%-32.3%$638.93MN/A-4.3832High Trading Volume Related Companies and Tools Related Companies Nurix Therapeutics Alternatives Ginkgo Bioworks Alternatives Terns Pharmaceuticals Alternatives AnaptysBio Alternatives Palvella Therapeutics Alternatives MeiraGTx Alternatives Siga Technologies Alternatives Olema Pharmaceuticals Alternatives Keros Therapeutics Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
